<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37716352</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-3791</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell reports. Medicine</Title><ISOAbbreviation>Cell Rep Med</ISOAbbreviation></Journal><ArticleTitle>Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study.</ArticleTitle><Pagination><StartPage>101195</StartPage><MedlinePgn>101195</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101195</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xcrm.2023.101195</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-3791(23)00362-2</ELocationID><Abstract><AbstractText>It is unknown if vaccination affects the risk of post-COVID-19 cardiovascular diseases (CVDs). Therefore, this retrospective cohort study examines the short-term and long-term risks of post-infection CVD among COVID-19 patients with different vaccination status utilizing data from electronic health databases in Hong Kong. Cox proportional hazards regression adjusted with inverse probability of treatment weighting is used to evaluate the risks of incident CVD (coronary heart disease, stroke, heart failure) and all-cause mortality in COVID-19 patients. Compared with unvaccinated patients, vaccinated patients have a lower risk of CVD and all-cause mortality, and the lowest risk is observed in those who completed three doses of vaccine. Similar patterns in the subgroups of different vaccine platforms, age, gender, Charlson comorbidity index, and disease severity are observed. These findings highlight a positive dose-response relationship between overall CVD risk reduction and the number of vaccine doses received.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Eric Yuk Fai</ForeName><Initials>EYF</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Anna Hoi Ying</ForeName><Initials>AHY</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Vincent Ka Chun</ForeName><Initials>VKC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Cheyenne I Ying</ForeName><Initials>CIY</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Boyuan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Francisco Tsz Tsun</ForeName><Initials>FTT</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Celine Sze Ling</ForeName><Initials>CSL</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Carlos King Ho</ForeName><Initials>CKH</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yiu</LastName><ForeName>Kai Hang</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Hung Fat</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Centre for Stem Cell Translational Biology, Hong Kong Special Administrative Region, China; Cardiac and Vascular Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Chak Sing</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian Chi Kei</ForeName><Initials>ICK</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK; Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. Electronic address: wongick@hku.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Esther Wai Yin</ForeName><Initials>EWY</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China. Electronic address: ewchan@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep Med</MedlineTA><NlmUniqueID>101766894</NlmUniqueID><ISSNLinking>2666-3791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722216">sinovac COVID-19 vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">incident CVD</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">omicron</Keyword><Keyword MajorTopicYN="N">post-COVID CVD</Keyword></KeywordList><CoiStatement>Declaration of interests E.Y.F.W. has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region and the Hong Kong Research Grants Council (RGC) outside the submitted work. F.T.T.L. has been supported by the RGC Postdoctoral Fellowship under the Hong Kong RGC and has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region outside the submitted work. C.S.L.C. has received grants from the Health Bureau of the Hong Kong Government, Hong Kong RGC, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen and personal fees from PrimeVigilance outside the submitted work. X.L. has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region, research and educational grants from Janssen and Pfizer, internal funding from the University of Hong Kong, and consultancy fees from Merck Sharp&#xa0;&amp; Dohme unrelated to this work. I.C.K.W. reports grants from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong RGC, the Hong Kong Health and Medical Research Fund in Hong Kong, National Institute for Health Research in the United Kingdom, the European Commission, and the National Health and Medical Research Council in Australia; consulting fees from IQVIA and World Health Organization; payment for expert testimony for Appeal Court of Hong Kong; and is a non-executive director of Jacobson Medical in Hong Kong and Therakind in the United Kingdom outside of the submitted work. E.W.C. reports grants from RGC (Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, and the Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region and a honorarium from Hospital Authority outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>16</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37716352</ArticleId><ArticleId IdType="pmc">PMC10591029</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2023.101195</ArticleId><ArticleId IdType="pii">S2666-3791(23)00362-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Terpos E., Ntanasis-Stathopoulos I., Elalamy I., Kastritis E., Sergentanis T.N., Politou M., Psaltopoulou T., Gerotziafas G., Dimopoulos M.A. Hematological findings and complications of COVID-19. Am. J. Hematol. 2020;95:834&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262337</ArticleId><ArticleId IdType="pubmed">32282949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Brady W.J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19. Am. J. Emerg. Med. 2020;38:1504&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Modin D., Claggett B., Sindet-Pedersen C., Lassen M.C.H., Skaarup K.G., Jensen J.U.S., Fralick M., Schou M., Lamberts M., Gerds T., et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142:2080&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682795</ArticleId><ArticleId IdType="pubmed">33054349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewek J., Jatczak-Pawlik I., Maciejewski M., Jankowski P., Banach M. COVID-19 and cardiovascular complications&#x2013;preliminary results of the LATE-COVID study. Arch. Med. Sci. 2021;17:818&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130484</ArticleId><ArticleId IdType="pubmed">34025853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranard L.S., Fried J.A., Abdalla M., Anstey D.E., Givens R.C., Kumaraiah D., Kodali S.K., Takeda K., Karmpaliotis D., Rabbani L.E., et al. Approach to acute cardiovascular complications in COVID-19 infection. Circ. Heart Fail. 2020;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126417</ArticleId><ArticleId IdType="pubmed">32500721</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. The COVID Heart&#x2014;One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks. JAMA. 2022;327:1113&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">35234824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang C.-Y., Wang S.-I., Wei J.C.-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Bluemke D.A., L&#xfc;scher T.F., Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 2022;43:1157&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed M.O., Banerjee A. Long COVID and cardiovascular disease: a learning health system approach. Nat. Rev. Cardiol. 2022;19:287&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8943785</ArticleId><ArticleId IdType="pubmed">35332308</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Butt A.A., National Study Group for COVID-19 Vaccination Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants. N.&#xa0;Engl. J. Med. 2021;385:187&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S., Champion J., Moultrie H., Bekker L.-G., Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N.&#xa0;Engl. J. Med. 2022;386:494&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-E., Huh K., Park Y.-J., Peck K.R., Jung J. Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. JAMA. 2022;328:887&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449799</ArticleId><ArticleId IdType="pubmed">35867050</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M., Mei X.W., Handunnetthi L., Dixon S., Zaccardi F., Shankar-Hari M., Watkinson P., Khunti K., Harnden A., Coupland C.A.C., et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 2022;28:410&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ali D., Elshafeey A., Mushannen M., Kawas H., Shafiq A., Mhaimeed N., Mhaimeed O., Mhaimeed N., Zeghlache R., Salameh M., et al. Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. J.&#xa0;Cell Mol. Med. 2022;26:636&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817142</ArticleId><ArticleId IdType="pubmed">34967105</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.Y., Chen H.M., Hsu C.Y. Prolonged peripheral seronegative spondyloarthritis following BioNTech coronavirus disease 2019 vaccination: A case report. Int. J. Rheum. Dis. 2023;26:774&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">36482057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler D.M. American Medical Association; 2022. p. e221809. (The Costs of Long COVID. In 5).</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar S., Sinha A., Banach M., Mittoo S., Weissert R., Kass J.S., Rajagopal S., Pai A.R., Kutty S. Cytokine storm in COVID-19&#x2014;immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front. Immunol. 2020;11:1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365905</ArticleId><ArticleId IdType="pubmed">32754159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan E.Y.F., Mok A.H.Y., Yan V.K.C., Wang B., Zhang R., Hong S.N., Chui C.S.L., Li X., Wong C.K.H., Lai F.T.T., et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA. 2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. J.&#xa0;Infect. 2022;85:e140&#x2013;e144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381942</ArticleId><ArticleId IdType="pubmed">35985416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Ramachandram D.S., Hasan S.S. Can COVID-19 vaccines improve cardiovascular outcomes? Trav. Med. Infect. Dis. 2022;48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9052786</ArticleId><ArticleId IdType="pubmed">35500844</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6&#xa0;months. N.&#xa0;Engl. J. Med. 2021;385:e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Tenforde M.W., Chappell J.D., Gaglani M., Ginde A.A., McNeal T., Ghamande S., Douin D.J., Talbot H.K., Casey J.D. Clinical Severity of, and Effectiveness of mRNA Vaccines against, Covid-19 from Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: Prospective Observational Study. bmj. 2022;376</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr F.B., Talisa V.B., Castro A.D., Shaikh O.S., Omer S.B., Butt A.A. COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. Nat. Commun. 2022;13:3647&#x2013;3656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233663</ArticleId><ArticleId IdType="pubmed">35752687</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Arocutipa C., Saucedo-Chinchay J., Mamas M.A., Vicent L. Travel Medicine and Infectious Disease; 2022. Influenza Vaccine Improves Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis.</Citation><ArticleIdList><ArticleId IdType="pubmed">35339690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan V.K.C., Wan E.Y.F., Ye X., Mok A.H.Y., Lai F.T.T., Chui C.S.L., Li X., Wong C.K.H., Li P.H., Ma T. Emerging Microbes&#xa0;&amp; Infections; 2022. Effectiveness of BNT162b2 and CoronaVac Vaccinations against Mortality and Severe Complications after SARS-CoV-2 Omicron BA. 2 Infection: A Case-Control Study; pp. 1&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553171</ArticleId><ArticleId IdType="pubmed">35980089</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., He S., Nasreen S., Sundaram M.E., Buchan S.A., Wilson S.E., Chen B., Calzavara A., Fell D.B., Austin P.C. Effectiveness of BNT162b2 and mRNA-1273 Covid-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe Covid-19 Outcomes in Ontario, Canada: Test Negative Design Study. bmj. 2021;374</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377789</ArticleId><ArticleId IdType="pubmed">34417165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Fischer H., Hong V., Ackerson B.K., Ranasinghe O.N., Frankland T.B., Ogun O.A., Zamparo J.M., Gray S., et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6&#xa0;months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17:543&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996&#x2013;1012.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Burckhardt R.M., Dennehy J.J., Poon L.L.M., Saif L.J., Enquist L.W. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. J.&#xa0;Virol. 2022;96:01973211&#x2013;e201921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8827020</ArticleId><ArticleId IdType="pubmed">34817198</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne A., Sperotto F., Chamberlain S., Baker A.L., Powell A.J., Prakash A., Castellanos D.A., Saleeb S.F., de Ferranti S.D., Newburger J.W., Friedman K.G. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021;6:1446&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356143</ArticleId><ArticleId IdType="pubmed">34374740</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D.Y., An S., Kaur A., Malhotra S., Vij A. Myocarditis after COVID-19 mRNA vaccination: A systematic review of case reports and case series. Clin. Cardiol. 2022;45:691&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286338</ArticleId><ArticleId IdType="pubmed">35652390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai F.T.T., Li X., Peng K., Huang L., Ip P., Tong X., Chui C.S.L., Wan E.Y.F., Wong C.K.H., Chan E.W.Y., et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case&#x2013;control study. Ann. Intern. Med. 2022;175:362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814917</ArticleId><ArticleId IdType="pubmed">35073155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudzik M., Lewek J., Kapusta J., Banach M., Jankowski P., Bielecka-Dabrowa A. Predictors of Long COVID in Patients without Comorbidities: Data from the Polish Long-COVID Cardiovascular (PoLoCOV-CVD) Study. J.&#xa0;Clin. Med. 2022;11:4980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9456773</ArticleId><ArticleId IdType="pubmed">36078910</ArticleId></ArticleIdList></Reference><Reference><Citation>HKSAR Government  . 2021. Third Dose COVID-19 Vaccination Arrangements for Persons under Certain Groups.https://www.info.gov.hk/gia/general/202111/03/P2021110300536.htm</Citation></Reference><Reference><Citation>HKSAR Government  . 2021. Further Expansion of COVID-19 Vaccination Arrangements from January 1.https://www.info.gov.hk/gia/general/202112/24/P2021122400509.htm</Citation></Reference><Reference><Citation>Glasheen W.P., Cordier T., Gumpina R., Haugh G., Davis J., Renda A. Charlson Comorbidity Index: ICD-9&#xa0;Update and ICD-10 Translation. Am. Health Drug Benefits. 2019;12:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684052</ArticleId><ArticleId IdType="pubmed">31428236</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart E.A., Lee B.K., Leacy F.P. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J.&#xa0;Clin. Epidemiol. 2013;66:S84&#x2013;S90.e1. doi: 10.1016/j.jclinepi.2013.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2013.01.013</ArticleId><ArticleId IdType="pmc">PMC3713509</ArticleId><ArticleId IdType="pubmed">23849158</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K., Ren S., Heath K., Dasmari&#xf1;as M.C., Jubilo K.G., Guo Y., Lipsitch M., Daugherty S.E. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. Bmj. 2022;376 doi: 10.1136/bmj-2021-068414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068414</ArticleId><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty S.E., Guo Y., Heath K., Dasmari&#xf1;as M.C., Jubilo K.G., Samranvedhya J., Lipsitch M., Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. Bmj. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O'Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozenne B., S&#xf8;rensen A., Scheike T., Torp-Pedersen C., Gerds T. riskRegression: Predicting the Risk of an Event using Cox Regression Models. R J. 2017;9:440&#x2013;460. doi: 10.32614/RJ-2017-062.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2017-062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>